Pharma BD Deal Intelligence

Dipharma SA / LogixX Pharma Limited

2026 · Acquisition/Merger · Complete

Swiss specialty pharmaceutical company Dipharma acquired LogixX Pharma, its UK commercial partner of nearly ten years, converting a distribution relationship into a wholly owned subsidiary and giving Dipharma its first direct commercial presence in the United Kingdom. LogixX, founded in 2010, markets medicines for rare and metabolic diseases in the UK and had commercialized Dipharma's nitisinone and, since 2023, sapropterin dihydrochloride. LogixX will continue to operate under its existing name. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals